Psychedelic approvals require active-placebo controls to defeat the bias of functional unblinding.
Because the intense sensory effects of psychedelic drugs immediately expose trial allocations, developers must deploy low-dose psychoactive comparators to prove true clinical efficacy to regulators.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Definium successfully secured clinical trial integrity by matching its therapeutic dose against a lower, non-therapeutic active-placebo dose designed to preserve blinding.
Under intense clinical pressure, developers are advocating for standardized clinical testing standards to normalize the evaluation and delivery of psychedelic compounds.
The FDA's final regulatory guidance formalizes clinical design requirements specifically aimed at minimizing the unblinding effects of psychoactive drugs.